ADMA Biologics (NASDAQ: ADMA) saw its stock price tumble 5.80% in post-market trading following the release of its first-quarter earnings report that fell short of analyst expectations. The biopharmaceutical company, which specializes in developing and commercializing specialty plasma-derived products, reported mixed results that disappointed investors despite showing significant year-over-year growth.

For the first quarter, ADMA Biologics reported adjusted earnings per share of $0.14, missing the analyst consensus estimate of $0.16 by 12.5%. Revenue for the quarter came in at $114.80 million, falling short of the projected $116.40 million by 1.37%. Despite the miss, these figures still represent substantial increases from the same period last year, with earnings per share up 75% and revenue growing 40.22% year-over-year.

In an effort to bolster investor confidence, ADMA Biologics announced a $500 million share repurchase program alongside its earnings release. The company also raised its revenue guidance for fiscal years 2025 and 2026 to over $500 million and $625 million, respectively, up from previous forecasts. Furthermore, ADMA projects its total annual revenues to exceed $1.1 billion by 2030. However, these positive long-term projections and the buyback announcement were overshadowed by the immediate reaction to the earnings miss, highlighting the market's focus on short-term performance metrics.